Janet Lo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5114119/publications.pdf

Version: 2024-02-01

218677 155660 3,242 55 68 26 citations h-index g-index papers 69 69 69 4073 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review. Open Forum Infectious Diseases, 2022, 9, ofac068.	0.9	20
2	Metabolic Consequences of Antiretroviral Therapy. Current HIV/AIDS Reports, 2022, 19, 141-153.	3.1	7
3	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e917-e925.	3.6	37
4	Gastrointestinal Dysfunction and HIV Comorbidities. Current HIV/AIDS Reports, 2021, 18, 57-62.	3.1	17
5	Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection. AIDS Research and Human Retroviruses, 2021, 37, 385-390.	1.1	7
6	Visceral Adiposity and Severe COVID-19 Disease: Application of an Artificial Intelligence Algorithm to Improve Clinical Risk Prediction. Open Forum Infectious Diseases, 2021, 8, ofab275.	0.9	17
7	Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. AIDS Research and Human Retroviruses, 2021, 37, 852-861.	1.1	9
8	A neurobiological link between transportation noise exposure and metabolic disease in humans. Psychoneuroendocrinology, 2021, 131, 105331.	2.7	10
9	Severe autoimmune hemolytic anemia following receipt of <scp>SARSâ€CoV</scp> â€2 <scp>mRNA</scp> vaccine. Transfusion, 2021, 61, 3267-3271.	1.6	29
10	Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs. Aids, 2021, 35, 81-90.	2.2	9
11	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2021, 8, ofab537.	0.9	19
12	Individual coronary plaque changes on serial CT angiography: Within-patient heterogeneity, natural history, and statin effects in HIV. Journal of Cardiovascular Computed Tomography, 2020, 14, 144-148.	1.3	9
13	Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity, 2020, 28, 749-755.	3.0	9
14	Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. Journal of Infectious Diseases, 2020, 222, 929-939.	4.0	16
15	Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1762-1775.	2.4	20
16	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 2019, 85, E607-E608.	1.1	20
17	ENDOTHELIAL SHEAR STRESS DERIVED FROM SERIAL NONINVASIVE CORONARY CTA: EFFECT OF WALL ELASTICITY IN A FEASIBILITY STUDY. Journal of the American College of Cardiology, 2019, 73, 1642.	2.8	O
18	Obesity and Fat Metabolism in Human Immunodeficiency Virus–Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications. Journal of Infectious Diseases, 2019, 220, 420-431.	4.0	64

#	Article	IF	CITATIONS
19	Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. Nutrition and Diabetes, 2019, 9, 6.	3.2	13
20	Gastrointestinal Barrier Breakdown and Adipose Tissue Inflammation. Current Obesity Reports, 2019, 8, 165-174.	8.4	34
21	Validity of hemoglobin A1c for diagnosing diabetes among people with and without HIV in Uganda. International Journal of STD and AIDS, 2019, 30, 479-485.	1.1	10
22	Amygdalar Metabolic Activity Independently Associates With Progression of Visceral Adiposity. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1029-1038.	3.6	15
23	978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV. Open Forum Infectious Diseases, 2019, 6, S36-S37.	0.9	6
24	341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States. Open Forum Infectious Diseases, 2019, 6, S181-S182.	0.9	3
25	Diet Quality Is Low and Differs by Sex in People with HIV. Journal of Nutrition, 2019, 149, 78-87.	2.9	16
26	Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. Aids, 2019, 33, 229-236.	2.2	18
27	Amygdalar activity predicts future incident diabetes independently of adiposity. Psychoneuroendocrinology, 2019, 100, 32-40.	2.7	24
28	Low Vitamin D is associated with Coronary Atherosclerosis in Women with HIV. Antiviral Therapy, 2019, 24, 505-512.	1.0	5
29	SUN-052 Low Vitamin D Is Associated with Coronary Atherosclerosis in Women with HIV. Journal of the Endocrine Society, 2019, 3, .	0.2	0
30	Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 105-110.	2.1	14
31	Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 421-428.	2.1	18
32	I-FABP Is Higher in People With Chronic HIV Than Elite Controllers, Related to Sugar and Fatty Acid Intake and Inversely Related to Body Fat in People With HIV. Open Forum Infectious Diseases, 2018, 5, ofy288.	0.9	25
33	Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine, 2018, 35, 58-66.	6.1	16
34	Differential relationships of hepatic and epicardial fat to body composition in HIV. Physiological Reports, 2017, 5, e13386.	1.7	9
35	Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infectious Diseases, 2017, 4, ofx227.	0.9	17
36	Relationship Between Measures of Adiposity, Arterial Inflammation, and Subsequent Cardiovascular Events. Circulation: Cardiovascular Imaging, 2016, 9, e004043.	2.6	50

#	Article	IF	CITATIONS
37	Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2016, 3, ofw062.	0.9	10
38	Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. Aids, 2016, 30, 583-590.	2.2	45
39	Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes and Endocrinology,the, 2016, 4, 598-610.	11.4	66
40	Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics. Open Forum Infectious Diseases, 2015, 2, oful 17.	0.9	54
41	Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. Aids, 2015, 29, 443-452.	2.2	60
42	Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2015, 2, e52-e63.	4.7	188
43	RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2873-2882.	3.6	75
44	The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH): Design of a pharmacogenetic Resource for Type 2 Diabetes. PLoS ONE, 2015, 10, e0121553.	2.5	20
45	2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. Aids, 2014, 28, 2061-2070.	2.2	65
46	Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men. European Journal of Preventive Cardiology, 2014, 21, 972-979.	1.8	12
47	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. Antiviral Therapy, 2014, 19, 805-811.	1.0	16
48	Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2013, 62, 1772-1778.	3.4	63
49	Noncalcified Coronary Atherosclerotic Plaque and Immune Activation in HIV-Infected Women. Journal of Infectious Diseases, 2013, 208, 1737-1746.	4.0	185
50	The Biology of Atherosclerosis: General Paradigms and Distinct Pathogenic Mechanisms Among HIV-Infected Patients. Journal of Infectious Diseases, 2012, 205, S368-S374.	4.0	50
51	Arterial Inflammation in Patients With HIV. JAMA - Journal of the American Medical Association, 2012, 308, 379.	7.4	411
52	Dyslipidemia and lipid management in HIV-infected patients. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 144-147.	2.3	44
53	Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients. Journal of Infectious Diseases, 2011, 204, 1227-1236.	4.0	374
54	Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. Aids, 2010, 24, 243-253.	2.2	287

#	Article	IF	CITATIONS
55	Adrenal function in HIV infection. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 205-209.	2.3	20
56	Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. Aids, 2010, 24, 2127-2130.	2.2	51
57	Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical Endocrinology, 2010, 72, 53-58.	2.4	46
58	Increased Coronary Artery Calcium Score and Noncalcified Plaque Among HIV-Infected Men: Relationship to Metabolic Syndrome and Cardiac Risk Parameters. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 495-499.	2.1	45
59	Effects of Low-Dose Growth Hormone Withdrawal in Patients With HIV. JAMA - Journal of the American Medical Association, 2010, 304, 272.	7.4	9
60	Increased aldosterone among HIV-infected women with visceral fat accumulation. Aids, 2009, 23, 2366-2370.	2.2	17
61	Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIVâ€infected patients and healthy adults. Clinical Endocrinology, 2009, 71, 815-822.	2.4	17
62	Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects. Metabolism: Clinical and Experimental, 2009, 58, 608-615.	3.4	13
63	Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation. JAMA - Journal of the American Medical Association, 2008, 300, 509.	7.4	80
64	Does growth hormone therapy benefit body composition and glucose homeostasis in girls with Turner syndrome?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 596-597.	2.8	4
65	Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 174-184.	2.1	56
66	Cardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk?. Current Opinion in HIV and AIDS, 2008, 3, 207-213.	3.8	14
67	Effects of TNF- \hat{l}_{\pm} neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E102-E109.	3.5	92
68	Effects of Obesity, Body Composition, and Adiponectin on Carotid Intima-Media Thickness in Healthy Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1677-1682.	3.6	99